Immune Deficiency due to IgG subclass

If you are suffering from chronic Fatigue, chronic pain, Fibromyalgia, recurrent infections, they you may have IgG or IgG subclass deficiency. If you have IgG subclass deficiency then vaccination can induce autoimmune disease in you. Certain immunodeficiencies are relatively simple to diagnose, being marked by grossly reduced serum levels of one or more classes of immunoglobulin. Other immunodeficiencies are less obvious and consequently more difficult to diagnose. The challenge is to accomplish the diagnosis and institute the appropriate treatment before permanent damage results. Immunoglobulin G (IgG) accounts for 70-75% of the total immunoglobulin pool in normal human serum. Unlike other immunoglobulins, IgG is not a single molecule but is composed of four distinct subclasses (IgG1, 2, 3 and 4), each having different functions. There is a wide variety of respiratory problems associated with IgG subclass deficiency, including recurrent otitis media, sinusitis, pneumonia, chronic obstructive airway disease, bronchiectasis and asthma. The way to test them is by getting a IgG subclass screen in your blood.   IgG 1 is the most abundant of the four subclasses and reaches 'adult' levels in early childhood. IgG1 provides the largest immune response and the dominant response to protein/polypeptide antigens. IgG2 is the most common IgG subclass deficiency and may also be associated with IgA deficiency. Recurrent respiratory infections in children (Haemophilus influenzae type b, Streptococcus pneumoniae) are particularly associated with IgG2 deficiency. 'Adult' levels of IgG2 are not usually reached until 6-7 years of age. IgG3 deficiency can manifest itself in recurrent respiratory infections with obstructive lung disease. It may be seen in association with IgG1 deficiency. Usually patients suffering from Chronic Fatigue Syndrome and Fibromyalgia will have low IgG3 deficiency. IgG4 deficiency may be associated with IgG2 and IgA deficiency in ataxia telangiectasia, frequently masked by normal levels of total IgG. Subclass deficiencies can also be associated with T-cell dysfunction. Elevated levels of IgG4 are seen in atopic dermatitis, asthma and some parasitic diseases. In a recent study of 56 adults with IgA deficiency the authors found the susceptibility respiratory tract infections was not related to the degree of IgA deficiency but was related to the deficiency of IgG4.

By support from Binding Site Laboratories   

 Causes of subclass Deficiencies and complete deficiency of individual IgG subclasses may have several consequences:

IgG1: IgG1 deficiencies often result in a decreased level of total IgG (hypogammaglobulinemia). A deficiency of this quantitatively most important subclass is often associated with recurrent infections and might occur in combination with (individual) deficiencies of other subclasses, e.g. IgG3 (36,64). In a recent evaluation of IgG1 concentrations in adults (n=1175) with suspected IgG subclass abnormalities, decreased IgG1 level were observed in 28% of the individuals (table IV).
Read et al. reported IgG1 subclass deficiencies in patients with chronic fatigue syndrome, whereas all other immunoglobulin isotypes were normal (65).
IgG1 deficiency is often associated with Common Variable ImmunoDeficiency.

IgG2: An IgG2 deficiency is offten associated with otitis media acuta and sinusitis, association with ataxia telangietasia and with System Lupus Erythematosus (SLE) has also been reported.
In about half of all IgG subclass deficiencies the IgG2 concentrations are decreased. An isolated IgG2 deficiency is associated with decreased responses to infections with encapsulated bacteria and after immunisation with polysaccharide antigens (38,66). These patients show recurrent respiratory tract infections with pneumococci and/or Haemophilus influenza type B (67,68,69). Low concentrations of IgG2 often occur in association with a deficiency in IgG4 and IgA.

IgG3: Along with IgG1, the IgG3 subclass is most frequently present in the antibody response to protein antigens. IgG3 deficiency has been associated with a history of recurrent infectious, leading to chronic lung disease. Decreased IgG3 levels are frequently associated with IgG1 deficiency (63).

IgG4: An IgG4 deficiency is difficult to assess. In healthy children, IgG4 may have very low concentrations. Methods that are used to measure IgG4 levels have not always been sensitive enough to distinguish complete absence of IgG4 from low-normal IgG4 levels. Thus, in most studies the assessment of IgG4 deficiency is hampered by the high frequency of undetectable IgG4 levels, which is especially common in young children. Although several studies have shown that a large population of patients with recurrent respiratory tract infection have low IgG4 concentrations, the significance of this finding is not clear since a low concentration of IgG4 also occurs in a substantial percentage of healthy children (63,70).

TABLE IV Frequency (%) of decreased IgG subclass concentrations in adults

4.3 IgG subclasses and allergy (85,86,87)

Among allergen-specific IgG antibodies in allergic individuals, there is a preponderance of IgG1 and IgG4, while IgG2 and IgG3 responses are small. Other findings in allergic patients include the following:

-Elevated IgG4 concentrations often occur in sera of patients with atopic eczema and dermatitis, probably as the result of prolonged antigenic stimulation (88).

-In allergy to many different allergens, allergen-specific IgG antibodies are predominantly of the IgG4 subclass and their levels increase during desensitisation therapy. In the antibody response to desensitization/immunotherapy, initially mainly IgG1 is formed, whereas IgG4 becomes more prominent after 1-2 years.

Allergen-specific IgG4 has often been regarded as a two-headed phenomenon: potentially harmful as well as potentially protective However, when more is found out about IgG4 antibodies, the harmful effects are hard to substantiate. The protective effects are still debated, but particularly from the field of parasitology the evidence is accumulating that IgG4 does, under certain conditions, effectively interfere with allergen-induced, IgE-medical effector cell triggering, i.e. IgG4 acts as a blocking antibody. Recent data indicate a striking similarity with respect to the type of antigen that triggers the IgG4 and IgE immune responses. Since a marked difference in epitope specificity exists between the IgG4 and IgE antibodies, only a fraction of the allergen-specific IgG4 can interfere effectively with IgE binding. The use of IgG4 antibody assays to monitor immunotherapy is justifiable, but its value should not be overrated. However, if no IgG4 antibody is induced by conventional immunotherapy, the therapy is likely to have been ineffective. An immunotherapy may be considered to be immunologically effective if a substantial increase (10 to 100 fold) in allergen-specific IgG4 is induced (89).

Decreased or increased levels of IgG subclasses in serum are associated with several other diseases, examples of which will be given here (90).

4.4.1 Infectious diseases (6)

In most infections the first antibodies to appear will be of the IgM class, while those of the IgG class will be produced later. In general, microbial protein antigens will mainly evoke antibody responses of the IgG1 and IgG3 subclasses, with a minor contribution of IgG2 and IgG4. On the other hand, polysaccharide antigens will predominantly induce IgG2 antibodies.

Some disease-specific observations:

- Pneumococcal otitis media in children is associated with a decreased level of IgG2.
- Patients with recurrent infections by encapsulated bacteria often show decreased levels of IgG2 and IgG4.
- Recurrent respiratory infections with bronchiectasis are often associated with decreased levels of IgG2, IgG3 and IgG4.
- Cystic fibrosis with chronic Pseudomonas aeruginosa infection is associated with an increased level of IgG2 and IgG3, the latter of which seems to be of prognostic significance.

4.4.2 Autoimmunity

In autoimmune diseases the levels of IgG subclasses do mostly not differ from those in healthy individuals, but specific autoantibodies show variable subclass restrictions: frequently, autoantibodies are of the IgG1 and IgG3 subclasses (91,92,118).
- Human rheumatoid factors (RF) are defined as IgG, IgA or IgM antibodies against the Fc fragment of immunoglobulin. In most cases, RF have been found to bind to the Fc fragments of IgG. As for their subclass specificity, most RF have been shown to react with IgG1, followed by IgG2 and IgG4. Binding of RF to IgG3 is rare.

- Abnormal IgG1: IgG2 ratios have been reported in patients suffering from connective tissue diseases. In case of a selective polyclonal increase of IgG1, one should be alert for the possibility of Sjögren's syndrome. It has been suggested that this immunoglobulin abnormality is the product of a restricted oligoclonal B cell response and may thus be the consequence of a benign B cell lymphoma (93,94,95,96).

- Autoantibodies to neutrophil cytoplasmic antigens (ANCA) are predominantly of the IgG1 and IgG4 subclass (97,98). Autoantibodies of the IgG3 subclass almost exclusively occur in patients with renal involvement(98).

4.4.3 Hemolytic disease of the newborn

Hemolytic disease of the new-born (HDN) is a disease in which new-born babies show an anemia caused by breakdown of the erythrocytes. This is triggered by maternal (IgG) antibodies, which have passes the placental barrier and bind to the foetal erythrocytes. During pregnancy, but most pronounced during childbirth, erythrocytes exchange between foetus and mother. If the foetal erythrocytes express antigens which are not present on the maternal erythrocytes (e.g. Rhesus D antigen), antibodies directed against these blood groups can be produced by the mother.
Antibodies to blood group antigens show a more or less IgG subclass-distinct profile. The influence of the IgG subclass of anti-Rhesus D antibodies on the severity of hemolytic disease of the newborn has been examined by many groups (99,100,101,102). In the majority of samples tested, both IgG1 and IgG3 antibodies were detected and the hemolytic disease was more severe than when only IgG1 was present. The significance of IgG3 antibodies is controversial. Some authors have suggested that IgG3 is always associated with overt hemolysis, but others could not confirm this. Blood group antibodies of the IgG4 subclass, in contrast to those of IgG1, IgG2 and IgG3 subclasses, are known not to cause clinical problems (hemolysis), which finding is mainly explained by the inability of such antibodies to activate complement(22,103,104,105).The determination of IgG subclasses is indicated especially when there is a clear discrepancy between serological findings and signs of increased red cell destruction in vivo (106).

As already mentioned in the previous sections, several studies indicate that (selective) IgG subclass deficiencies may be associated with disease. Specific examples are: bronchiectasis and severe, recurrent stages of otitis media, sinusitis, pneumonia and bronchitis. The possibility of an IgG subclass deficiency should be considered in all children with recurrent infections and chronic obstructive bronchitis. The association between IgG2 deficiency and severe recurrent infections of the respiratory tract in young children, caused by encapsulated bacteria, have led to an increasing demand for the determination of IgG subclasses in sera from children. However, it should be kept in mind that IgG subclass deficiencies in children may be transient. The levels of IgG2 increase relatively late in childhood. Thus, when low IgG2 levels are found in children below the age of 2-3 years, it is advisable to monitor this level in the course of time, since it may be due to a temporary maturation block. Obviously, IgG subclass deficiencies may also occur in all patients at risk for infections due to immunodeficiency, such as occurs e.g. in haematopoietic stem cell transplantation.

In general, IgG subclass levels should be measured whenever the total IgG level is decreased. However, and IgG subclass deficiency is not excluded by a normal or even high total IgG concentration (62). Therefore, it is essential to measure individual IgG subclass levels (107). A correct diagnosis is essential in choosing the appropriate therapy (108). There are several specific disease conditions in which measurement of IgG subclasses is recommended:

- Several specific infections, such as meningitis caused by pneumococci, Haemophilus influenzae (B) and meningococci or osteomyelitis and severe pneumonia;
- Recurrent purulent infections of the upper and lower respiratory tract (it is advisable to assess the actual causative agent(s) by means of serology and culture of the micro-organisms in vitro);
- Bronchiectasias and/or purulent infections of unclear etiology, such as cystic fibrosis, immotile cilia syndrome (Kartagener syndrome), or a history of earlier infections like measles-pneumonia;
- IgA-deficiency associated with infectious disease (pneumonia, sinusitis, etc.);
- Diseases mentioned in chapters 4.2 and 4.4.

4.5.1 Assessment of immune status

The determination of IgG subclass levels is included in the routine laboratory tests for the assessment of the immune status. It is used as a parameter of humoral immunity. For diagnostic testing of pediatric and adult patients with recurrent infections in whom an immunodeficiency is suspected, the following protocol has been developed by the Netherlands Working Party for Immunodeficiencies (109). A characteristic feature of this protocol for the assessment of immunological competence is a graduation in stages of tests with more or less increasing complexity.

A. Patient's history

-Infections: Localization, frequency, duration, reaction to antibiotic therapy, nature of the infectious micro-organism(s): viruses, bacteria, fungi, protozoa
-Allergy: asthma, eczema, diarrhea
-Family: early deaths of other children, occurrence of severe or unusual infections, malignancies, auto-immune diseases

B. Physical examination

- assessment of sites of infection (ear/nose/throat, lungs, abdomen, urogenital, skin)
- swelling or absence of lymphoid tissue (lymph nodes, adenoid, tonsils, spleen)

- differential leucocyte count (basophils, eosinophils, neutrophils, lymphocytes, monocytes)
- haemolytic complement (classical and alternative pathway: CH50 and AP50
- opsonic activity of patient's serum
-phagocytic activity of patient's granulocytes

D. Specific immunity

Humoral:

- serum levels of total IgG,IgM,IgA and IgE
- serum levels of IgG subclasses
- titres of isohaemagglutinins
- levels of IgA and IgM in saliva

Cellular:

Determination of lymphocyte subpopulations:

- T cells (CD3+)
- B cells (CD19+)
- T helper/inducer cells (CD3+, CD4+)
- T suppressor/cytotoxic cells (CD3+, CD8+)
- activated T cells (CD3+, HLA-DR+)
- NK cells (CD3-, CD16+, CD56+)

- Specific antibody responses before and after vaccination (Diphtheria/Tetanus/Polio, Haemophilus influenzae B conjugate, Pneumovax, Meningovax type A/C). Since patients with IgG subclass deficiencies frequently suffer from infections with pneumococci and Haemophilus bacteria, it is important to measure specific antibodies against these micro-organisms, before and after vaccination, using the polysaccharide- or conjugate vaccines now commercially available.

- Delayed type hypersensitivity skin tests (Tuberculin, Candida, Trichophyton, Proteus, Tetanus, Diphteria, Streptococcal antigens)

- T cell stimulation in vitro by mitogens and antigens.

For individuals with IgG subclass deficiencies who also develop clinical symptoms (e.g. recurrent infections), treatment should be considered. Treatment of such patients will generally consist of anti-microbial therapy, immunoglobulin substitution and vaccinations.

Conservative treatment, comprising early antibiotics treatment during infections, prophylactic antibiotic treatment in selected individuals and supportive symptomatic therapy should be the first line of treatment, sometimes supplemented with intravenous immunoglobulin. In patients with primary specific immunodeficiency who have significantly diminished serum IgG levels and/or demonstrated defects in antibody production, intravenous immunoglobulin replacement therapy is currently most often used, since administration of immunoglobulins will reduce the incidence of bacterial and viral infections.
Patients with selective IgG subclass deficiency may benefit from IgG replacement (WHO-report)(110).

The maturation of an immune response can be enhanced by repeated vaccination. Vaccination with Diphtheria/Tetanus/Polio proteins (T cell-dependent antigens) from the age of three months is generally performed. Active immunization against polysaccharide antigens (T cell-independent antigens) is ineffective until about the age of 18 months, because of the slow ontogeny of the anti-polysaccharide immune response. By coupling the polysaccharide antigens to protein carriers conjugate-vaccines), the T cell-independent response is changed into a T cell-dependent one, leading to an effective response against polysaccharide antigens in young children (111, 112, 113, 114). In IgG2-deficient patients, only a marginal compensating mechanism exists, as illustrated by the impaired anti-polysaccharide response in all other immunoglobulin isotypes. This poor responsiveness can be partly bypassed by using conjugate-vaccines.
Nevertheless, it should be kept in mind that active vaccination procedures may fail, due to a deficient humoral immunity.

7 References

1. Roitt I., J.Brostoff, and D. Male.: "Immunology", Mosby., London, England, (1996) fourth edition.
2. Stitis, D.P.,J.D.Stobo,J.V. Wells: "Basic and Clinical Immunology" 7th edition, Appleton and Lange (1991).
3. Spiegelbert H.L.: "Biological activities of Igs of different classes and subclasses". Adv.Immunol.19, 259 (1974).
4. Goodman, J.W.: "Immunoglobulin structure and function" in: Basic and clinical Immunology D.P., Stites et al.Lange, Med.Pub.Los Altos,CA,P.27 (1987).
5. Flanagen J.G. and T.H. Rabbits: " Arrangement of human immunoglobulin heavy chain constant region genes implies evolutionary duplication of a segment containing Y,E and a genes'. Nature 300,709 (1982).
6. Hammarstrom, L. and C. Smith: "IgG subclasses in bacterial infections". Monogr.Allergy 19,122 (1986).
7. Bottaro A. M., DeMarchi and G.G. DeLange: "Human IGHC locus restriction fragment length polymorphisms in IgG4 deficiency: evidence for a structural IGHC defect". Eur.Journal of Immunology, 19, 2159 (1989).
8. Mayumi M.et al.: "IgG subclass expression by human B lymphocytes and plasma cells: B lymphocytes precommitted to IgG subclass can be preferentially induced by polyclonal mitogens with T cell help, J.Immuno. 130,671 (1983).
9. Mongini,P.K.A., W.E.Paul and E.S.Metcalf: "T cell regulation of immunoglobulin class expression in the antibody response to trinitrophenyl-ficoll". J.Exp.Med.155, 884 (1982).
10. LeBich-Thuy and J.P. Revillard:"Modulation of polyclonally activated human peripheral B cells by aggregated IgG and by IgG-binding factors: Differential effect on IgG subclass synthesis". J.Immunol.133, 544 (1984).
11. Grey,H.M. and H.G. Kunkel: "H-chain subgroups of myeloma proteins and normal globulins", J.Exp.Med. 120,253 (1964).
12. Gergely J., : "Structural studies of Igs". Immunochemistry 4, 101 (1967).
13. World Health Organisation: "WHO Technical Series". Report no. 35,953 (1966).
14. Jefferis,R.: "Polyclonal and monoclonal reagents specific for IgG subclasses". Monogr.Allergy 19,71 (1986).
15. Reimer,C.B.,D.J.Phillips et al.:"Evaluation of 31 mouse monoclonal antibodies to human IgG epitopes". Hybridoma 3,263 (1984).
16. Vlug,A. and P. van Remortel: "The structure and function of human IgG subclasses". Eur.Clin.Lab. 8,26 (1989).
17. Schur,P.H.:"IgG subclasses-a review". Ann.Allergy 58,89(1987).
18. Shakib,F.and D.R. Stanworth:"Human IgG subclasses in health and disease; a review". Ric.Clin.Lab.10,561 (1980).
19. French,M.:"Serum IgG subclasses in normal adults". Monograph. Allergy 19,100 (1986).
20. Burton,D.R.,L.Gregory and L.Jefferis:"Aspects of the Molecular Structure of the IgG subclasses". Monograph.Allergy 19,7(1986)
21. Pumphrey,R.:"Computer models of the human Immunoglobulins". Today 7,174(1986).
22. Brekke,O.H.,T.E.Michaelsen and I.Sandie:"The structural requiremnts for complement activation by IgG: does it hinge". Immunol.Today 16,85 (1995).
23. Coleman,P.M. et al.:"Structure of the human Ab molecule K01 (IgG1): an electron density map at 5 A resolution". J.Mol. Biol. 100,257 (1976).
24. Abramovr,V.M. et al.:"Conformational properties of human IgG subclasses". Biochim.Biophys.Acta 742,295 (1983).
25. Michaelsen,T.E. et al.:"Human IgG3 is decreased and IgG1/2/4 are unchanged in MW by mild reduction and reoxidation without any major change in effector function". Mol.Immunol.30,35 (1993).
26. Saluk,P.H. and L.W. Clem:"Unique molecular weight of the heavy chain of human IgG3 proteins".J.Immunol.107,298(1971).
27. Jefferis,R. and D.R. Stanworth:"The relationship between pa pain sensitivity of human Immunoglobulins and their heavy chain subclass". FEBS Symp.15,213 (1969).
28. Skvaril,F. et al.:"IgG subclass composition and immunochemical characterisation of plasmin-treated human immunoglobulin". Vox Sang.30,334 (1976).
29. Gergely,J.et al.:"IgG myeloma subclass typing by tryptic di gestion of whole sera". Immunochemistry 9,589 (1972).
30. Turner,M.W. et al.:"Pepsin digestion of human G-myeloma proteins of different subclasses".Clin.Exp.Immunol.7,627(1970).
31. Van Loghem,E.:"Allotypic Markers". Monographs Allergy 19,40 (1986).
32. De Lange,G.G.:"Polymorphisms of human immunoglobulins: Gm,Am, Em and Km allotypes". Exp.Clin.Immunol.6.7 (1989).
33. Scharfield,M.S. and E. Van Loghem:"Human immunoglobulin allotypes". in:Handbook of Exp.Imm.part 3, chapter 94.(D.M.Weir ed.), Blackwell Scientific Publications (1986).
34. Soderstrom,T., A.Enskog, B.E. Samuelson and B. Cedergen: "Immunoglobulin subclass (IgG3) restriction of anti-P and anti-Pk antibodies in patients of the rare P blood group". J.Immunol. 134,1 (1985).
35. Burton,D.R. and J.M.Woof:"Human antibody effector function". Adv.Immunol. 51,1-84 (1992).
36. Bredius, R.G.M.:"Effector functions of antibacterial IgG subclass antibodies". Thesis, Amsterdam, 1994.
37. Ferrante,A.,L.J.Beard and R.G. Feldman:"IgG subclass distribution of antibodies to bacterial and viral antigens". Pediatr, Infect.Dis.J. 9,S16 (1990).
38. Siber,G.R., P.H.Schur, A.C. Aisenberg et al.: "Correlation between serum IgG2 concentrations and the antibody response to bacterial polysaccharide antigens". New Engl.J.Med. 303,178 (1990).
39. Morell,A., J.E.Doran and F. Skvaril: "Ontogeny of the humoral response to group A streptococcal carbohydrate: Class and IgG subclass composition of antibodies in children". Eur.J.Immuno- l. 20,1513 (1990).
40. Aalberse R.C., R.Van der Gaag and J. Van Leeuwen: "Serological aspects of IgG4 antibodies I. Prolonged immunisation results in an IgG4-restricted response:. J.Immunol. 130,722(1983).
41. Van de Winkel,J.G.J. and C.L. Andrson: "Biology of human immun oglobulin G Fc receptors". J.Leucocyte Biol. 49,511(1991).
42. Weinberg,G.A., D.M. Granoff et al.:"Functional activity of different IgG subclass antibodies against type b capsular poly- saccharide of haemophilus influenzae".J. Immunol.,136,4232 (1986).
43. Bjornson,A.B.and J.S.Lobel.: "Direct evidence that decreased serum opsonisation of Streptococcus pneumoniae via the alternative complement pathway in sickle cell disease is related to antibody deficiency". J. Clin.Invest.,79, 388 (1987).
44. Kujpers,T.W., R.S. Weenig and T.A. Out:"IgG subclass deficiencies and recurrent pyogenic infections:Unresponsiveness a gainst bacterial polysaccharide antigens". Immunol.Clin.X,157 (1991).
45. Van de Winkel,J.G.J. and P.J.A.Capel (eds.):"Human IgG Fc receptors'.R.G. Landes Company,Austin,USA (1996).
46. Van de Winkel,J.G.J. and P.J.A. Capel: "Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications". Immunol.Today,14,215-221 (1993).
47. Bredius,R.G.M., B.H.F. Derkx, C.A.P.Fijen, T.P.M. de Wit, M.de Haan, R.S.Weening, J.G.J. van de Winkel and T.A.Out: "Fcg Rlla (CD32) polymorphism in fulminant meningococcal spectic shock in children". J.Infect. Dis. 70,848(1994).
48. Ravetch,J.V. and J.P. Kinet: "Fc receptors". Ann.Rev.Immunol.9, 457 (1991).
49. Ernst,L.K.,J.G.J. van de Winkel,I.M. Chiu and C.L.,Anderson: "Three genes for the human high-affinity Fc receptor for IgG (FcyRII) encode for distinct transcription products". J.Biol. Chem.,267,5692(1991).
50. Bredius,R.G.M., T.A. Out and R.S. Weening:"Functionele eigen schappen van IgG subklasses-antistoffen in de bacteriele afweer". Tijdschr.Kindergeneeskunde 63,209(1995).
51. Parren P., P.W.H.I.Parren, P.A.M.Warmerdam, L.C.M.Boeje, J.Arts, N.A.C. Westerdaal, A.Vlug,P.J.A. Capel, L.A. Aarden and J.G.J. van de Winkel: "On the interaction of IgG subclasses with the low-affinity Fcg RIIa (CD32) on monocytes,neutrophils and platelets". J.Clin.Invest.90,1537(1992).
52. Huizinga,T.W.J.M.Kerst,J.H.Nuijens,A.Vlug,A.E.G.Fr. von dem Borne,D.`Roos and P.A.T. Tetteroo: "Binding characteristics on dimeric IgG subclass complexes to human neutrophils" J. Immunol. 142,2359 (1989).
53. Bredius,R.G.M., C.A.P.Fijen, M.de Haas:" Role of neutrophil FcyRIIa (CD32) and FcyRIIb (CD16) polymorphic forms in phagocytosis of human IgG- and IgG3- opsonisised bacteria and erythrocytes". Immunology 83, 624 (1994).
54. Erbe,D.V., E.R. Pfefferkorn and M.W. Fanger: "Functions of the various human IgG Fc receptors in mediating killing to Toxo plasma gondij". J.Immunol. 146,3145 (1991).
55. Eijen,C.A.P.,R.G.M. Bredius and E.J. Kuiper: Ann.Int.Med. 119, 636 (1993).
56. Lee, S.I.,D.C.Heiner and D.Wara: "Development of serum IgG subclass levels in children". Monogr.Allergy 19,108 (1986).
57. French,M.: Serum IgG subclasses in normal adults:. Monogr. Allergy 19, 100 (1986).
58. French, M.A.H. and G.Harrison:`"Serum IgG subclass concentrations in healthy adults: a study using monoclonal sera". Clin. Exp. Immunology, 56,473 (1984).
59. Nieuwenhuys,E.J. and T.A. Out: "Comparison of normal values of IgG subclasses:. Coll.Protides of the biological fluids, Volume 36.71-79 (1989).
60. Vlug,A., E.J.Nieuwenhuys,R.V.W. van Eyk, H.G.M. Geertzen and A. J. van Houte: "Nephelometric measurement of human IgG sub classes and their reference ranges". Ann.Biol.Clin, 52,561 (1994).
61. Morell,A.: "Clinical relevance of IgG subclass deficiencies". Ann.Biol.Clin. 52,49 (1994).
62. Aucouturier,P., M.Mariault, C.Lacombe and J.L.Preud'homme: "Frequency of selective IgG subclass deficiency": A Reappraisal", Clin.Immunol.Immunopath.63,289 (1992).
63. Herrod,H.H.:"Management of the patient with IgG subclass deficiency and/or selective antibody deficiency". Annals of Allergy 70,1 (1993).
64. Skvaril,F.and R. Scherz: "IgG subclasses in IgA-deficient patients with anti-IgA antibodies". Monogr.Allergy 20,164 (1986).
65. Read,R., G.Spickett, J. Harvey,A.J.Edwards and H.E.Larson:"IgG1 subclass deficiency in patients with chronic fatigue syndrome". Lancet, 30, 241 (1988).
66. Umetsu,D.T., D.M. Ambrosino, I.Quinti, G.Siber and R.S. Geha: "Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG subclass deficiency". New Eng.J.Med.313, 1247 (1985).
67. Scott,M.G., P.G. Shackleford, D.E.Briles et al.: "Human IgG subclasses and their relation to carbohydrate antigen immunocompetence", Diagn.Clin.Immunol.5,241 (1988).
68. Lucas,A.H. and D.M.Granoff: "Functional differences in idiotypically defined IgG antipolysaccharide antibodies elicited by vaccination with H. influenzae type B polysaccharide-protein conjugates".J.Immunol. 154,4195 (1995).
69. Hammarstrom,L., R.A.Insel, M.A.Persson and C.I.Smith: "The IgG subclass preference of selected naturally occuring anti-poly-saccharide antibodies". Monogr.Allergy 23,18 (1988).
70. Moss,R.B., M.A.Carmack and S. Esrig: "Deficiency of IgG4 in children: association of isolated IgG4 deficiency with recurrent respiratory tract infections". J.Pediatr. 120,161 (1992).
71. Bjorkander,J., V.A. Oxelius, R.Soderstrom and L.A. Hanson: "Immunoglobulin treatment of patients with selective IgG sub classes and IgA deficiency states". Monogr.Allergy 23,160 (1988).
72. Out,T.A. et al.Clin.Exp.Immunol. 64,510 (1986).
73. Seligmann,M., P.Aucontane, F. Danon and J.L.Preud'homme: "Changes in serum immunoglobulin pattern in adults with common variable immunodeficiency". Clin.Exp.Immunol. 84, (1991).
74. Wedgwood,R.J., H.D. Ochs and V.A. Oxelius: "IgG subclass levels in the serum of patients with primary immunodeficiency". In Ref. 1 pp. 80-89 (1986).
75. Oxelius, V.A.: "IgG subclasses in primary immunodeficiency disorder". Monogr.Allergy 19,156 (1986).
76. Nahm,M.H., R.M. Blaese and M.J. Crain et al.: "Patients with Wiskott-Aldrich syndrome have normal IgG2 levels". J. of Im munology, 137,3484 (1986).
77. Berkel,A.I.: "Studies of IgG subclasses in ataxia telangiectasia patients". Monogr.Allergy 20,100 (1986).
78. Aucouturier,P., C.Bremard-Oury and C. Griscelli et al.: "Serum IgG subclass deficiency in ataxia telangiectasia".Clin. Exp. Immunology, 68, 392 (1987).
79. Bentur,L., E.Nisbet Brown, H. Levison and C.M.Roifman: "Lung disease associated with IgG subclass deficiency in chronic mucocutaneous candidiasis". J.Pediatr. 118,82 (1991).
80. Scoular,A., G.D. Corcoran, A. Malin et al,: "Fusobacterium nucleatum bacteremia with multiple liver abscesses in an HIV-1 antibody-positive man with IgG2 deficiency". J.Infect.Dis.24, 321 (1992).
81. Bartmann,P., I.Grosch-Worner, V. Wahn and B.H. Belohradsky: "IgG2 deficiency in children with HIV-infection". Eur.J. Pediatr. 150,234 (1991).
82. Parkin,J.M., M. Helbert, C.L. Hugues and A.J.Pinching: "Immuno globulin G subclass deficiency and susceptibility to pyogenic infections in patients with AIDS-related complex and AIDS,3, 37 (1989).
83. Bakemeier,R.F., N.G. Hildreth and D.H.Ryan: "Lymphocyte subclasses and immunoglobulin in adults receiving radiation treatment in infancy for thymic enlargement". Radiat.Res.107, 367 (1986).
84. Aucouturier,P. and A. Barra et al.: "Long lasting IgG subclass and anti-bacterial polysaccharide antibody deficiency after bone marrow transplantation". Blood, 70, 779 (1987).
85. Merrett,J., R.S.C. Barnetson, M.L.Burr and T.G. Merrett: "Total and specific IgG4 antibody levels in atopic eczema". Clin.Exp. Immunol.56, 646 (1984).
86. Lucas,A.H.: "IgG subclass restricted immune responses to allergens". Springer Semin.Immunopathol. 12,385 (1990).
87. Urbanek,R.: "IgG subclasses and subclass distribution in allergic disorders". Monogr.Allergy 23,33 (1988).
88. Shakib,F.:"The IgG4 subclass". Monogr.Allergy 19,223 (1986).
89. Aalberse,R.C., F.Van Milligen,K.Y. Tan and S.O. Stapel,: "Allergen-specific IgG4 in atopic disease". Allergy, 48,559 (1993).
90. Jefferis,F. and D.S. Kumararatne: "Selective IgG subclass deficiency: quantification and clinical relevance". Clin.Exp. Immunol. 81, 357 (1990).
91. Yount,W.J., P.Cohen and R.A. Eisenberg: "Distribution of IgG subclasses among human autoantibodies to Sm, RNP, dsDNA and IgG rheumatoid factor". Monogr.Allergy 23, 41 (1988).
92. Gharavi,A.E., E.N.Harris,M.D.Lockshin et al.: "IgG subclass and light chain distribution of anticardiolipin and anti-DNA anti bodies in SLE". Ann.Rheum.Dis. 47,286 (1988).
93. Kay,R.A., K.J.Wood, R.M.Bernstein,P.J.L. Holt and R.S.H. Humphrey "An IgG subclass imbalance in connective tissue disease". Ann. Rheum.Dis. 47,536 (1988).
94. Meilof,J.F., K.M.Hebeda, J.de Jong and R.J.T. Smeenk: "Analysis of heavy and light chain use of lupus-associated anti-La/SS-B and anti-Sm autoantibodies reveals two distinct underlying immunoregulatory mechanism". Res.Immunol. 143,711 (1992).
95. Hay,E.M., A.J. Freemont, R.A. Kay, R.M.Bernstein, P.J.L. Holt and R.S.H. Pumphrey: "Selective polyclonal increase of immunoglobulin G1 subclass: a link with Sjogren's Syndrome". Ann.Rheum. Dis. 49,373 (1990).
96. Eriksson,P.,G. Almroth, T.Denegerg and F.D. Lindstrom:"IgG2 deficiency in primary Sjogren's Syndrome and Hypergammaglobulinemic Purpura". Clin.Immunol.Immunopath. 70, 60 (1994).
97. Brouwer,E., J.W.Cohen Tervaert, G. Horst, M.G. Huitema, M.Van der Giessen, P.C. Limburg and C.G.M. Kallenberg: "Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic auto antibodies in patients with Wegener's granulomatosis and clinically related disorders". Clin.Exp.Immunol. 83,379(1991).
98. Mellbye,O.J., T.E. Mollnes and L. Slettevoll Steen: "IgG subclass distribution and complement activation ability of autoantibodies to neutrophil cytoplasmic antigens (ANCA)". Clin. Immunol. Immunopath. 70,32 (1994).
99. Engelfriet,C.P., A.E.G. Van den Borne, D.Beckerd and J.J. Van Loghem: "Autoimmune haemolytic anemia: serological and immuno chemical characteristics of the autoantibodies; mechanisms of cell destruction". Ser. Haematol. 7, 328 (1974).
100. Zupanska,B., E.Brojer,Y. Richards et al.: "Serological characteristics of maternal anti-Rh(D) antibodies in predicting the severity of haemolytic disease of the newborn". Vox Sang 56, 247 (1989).
101. Garratty,G. And S.J. Nance: "Correlation between in vivo haemolysis and the amount of red cell-bound IgG measured by flow cytometry". Transfusion 30, 617 (1990).
102. Pollock,J.M. and J.M. Bowman: "Anti-Rh(D) IgG subclasses and severity of Rh haemolytic disease of the newborn". Vox Sang 59, 176 (1990).
103. Feinstein, A., N. Richardson and M.J.Taussig: "Immunoglobulin flexibility in complement activation". Immunol. Today 7,169 (1986).
104. Michaelsen,T.E., B.Frangione and E.C. Franklin: "Primary structure of the hinge region of human IgG3. Probable quadrup lication of a 15-amino acid residue basic unit". J.Biol.Chem. 252, 883 (1977).
105. Abrahamson,N. and P.H. Schur: "The IgG subclasses of red cell antibodies and relationship to monocyte binding". Blood 40, 500 (1972).
106. Engelfriet,C.P., G.G. De Lange, M. Zijdeveld and N.Mass: "The determination of the subclass of IgG red cell antibodies". Biotest bulletin 1:2 (1986).
107. Shield,J.P.H., S.Strobel,R.J. Levinsky and G. Morgan.: "Immunodeficiency presenting as hypergamma-globulinaemia with IgG2 subclass deficiency". Lancet, 340, 448 (1992).
108. Preud'homme,J.L. and L.A. Hanson: "IgG subclass deficiency". Immunodefic Rev. 2, 129 (1990).
109. Vossen,J.M., Zegers,B.J.M.: "Diagnostisch onderzoek bij patienten met een verdenking van een immunologische afweerstoornis". Tijdschr.Kindergeneesk. 56, 174 (1988).
110. WHO Scientific group: "Primary immunodeficiency diseases". Clin.Exp. Immunol. 99, Supplement 1,January 1995.
111. Peltola,H., H.Kayhty, A. Sivonen and P.H. Makela: "Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100.000 vaccinees 3 months to 5 years of age in Finland". Pediatrics, 60, 730 (1977).
112. Insel,R.A., P.W. Anderson: "Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants". J.Exp.Med. 163,262 (1986).
113. Eskola,J., H. Peltola et al.: "Antibody levels achieved in infants by course of Haemophilus influenzae type b polysaccharide/Diphtheria Toxoid conjugate vaccine". Lancet, 1184 (1985).
114. Cryz, S.J., J.C. Sadoff et al.: "Characterisation of the human response to a Pseudomonas aeruginosa, O polysaccharide- toxin A conjugate vaccine". J.Clin. Invest. 701 (1987).
115. Klein,F., F. Skvaril, R. Vermeeren et al.: "The quantification of human IgG subclasses in reference preparations". Clin.Chim. Acta 150, 119 (1985).
116. Hammarstrom L. and C. Smith. Prot. Biol. Fluids 36,133(1989).
117. Schuurman,J.;Çhimeric monoclonal antibodies to the mite allergen Dep p2'. PhD Thesis, University of Amsterdam, The Netherlands (1997).
118 Maran,R., Dueymes,M., Le Corre R., et al.; 'IgG subclasses of human autoantibodies'. Ann. Medicine Interne 148:29 (1997)